Publications by authors named "Scott Slough"

Claim this Profile
P
Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors.
Geoffrey I Shapiro, Raoul Tibes, Michael S Gordon, Bryan Y Wong, Joseph Paul Eder, Scott Slough

Clin Cancer Res· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo characterisation of the small-conductance KCa (SK) channel activator 1-ethyl-2-benzimidazolinone (1-EBIO) as a potential anticonvulsant.
Neil J Anderson, Scott Slough, William P Watson

Eur J Pharmacol· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First demonstration of a functional role for central nervous system betaine/{gamma}-aminobutyric acid transporter (mGAT2) based on synergistic anticonvulsant action among inhibitors of mGAT1 and mGAT2.
H Steve White, William P Watson, Suzanne L Hansen, Scott Slough, Jens Perregaard

J Pharmacol Exp Ther· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence that the novel imidazoline compound FT005 is an alpha(2)-adrenoceptor agonist.
Scott Slough, Gerald Guillaumet, Peter V Taberner

Br J Pharmacol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis